Enanta Pharmaceuticals, Inc.
$13.78
▲
1.31%
2026-04-21 06:39:01
www.enanta.com
NMS: ENTA
Explore Enanta Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$409.17 M
Current Price
$13.78
52W High / Low
$17.15 / $4.83
Stock P/E
—
Book Value
$4.36
Dividend Yield
—
ROCE
-36.76%
ROE
-60.01%
Face Value
—
EPS
$-3.21
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
120
Beta
1
Debt / Equity
152.6
Current Ratio
4.44
Quick Ratio
4.21
Forward P/E
-6.39
Price / Sales
6.11
Enterprise Value
$416.8 M
EV / EBITDA
-6.12
EV / Revenue
6.22
Rating
Buy
Target Price
$18.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
| 2. | Rapport Therapeutics, Inc. | $37.14 | — | $1.9 B | — | -25.36% | -28.22% | $42.27 / $7.73 | $10.14 |
| 3. | Enlivex Ltd. | $0.88 | — | $207.92 M | — | -0.65% | 1.26% | $2.1 / $0.66 | $8.15 |
| 4. | Milestone Pharmaceuticals Inc. | $2.04 | — | $247.1 M | — | -62.4% | -2.3% | $3.06 / $0.77 | $0.34 |
| 5. | Lineage Cell Therapeutics, Inc. | $1.65 | — | $410.99 M | — | -21.52% | -1.05% | $2.09 / $0.4 | $0.18 |
| 6. | PepGen Inc. | $1.73 | — | $117.5 M | — | -58.05% | -67.39% | $7.8 / $1.01 | $2.14 |
| 7. | Filana Therapeutics, Inc. | $1.75 | — | $84.54 M | — | -128.99% | -82.66% | $2.27 / $1.53 | $1.54 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 18.61 M | 15.12 M | 18.31 M | 14.93 M | 16.96 M |
| Operating Profit | -11.25 M | -18.39 M | -18.89 M | -24.53 M | -23.54 M |
| Net Profit | -11.94 M | -18.7 M | -18.25 M | -22.64 M | -22.29 M |
| EPS in Rs | -0.41 | -0.64 | -0.63 | -0.78 | -0.77 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 65.32 M | 67.64 M | 79.2 M | 86.16 M |
| Operating Profit | -85.35 M | -121.69 M | -137.21 M | -123.84 M |
| Net Profit | -81.89 M | -116.05 M | -133.82 M | -121.75 M |
| EPS in Rs | -2.82 | -4 | -4.61 | -4.2 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 280.73 M | 376.65 M | 462.27 M | 375.41 M |
| Total Liabilities | 216.01 M | 247.84 M | 245.54 M | 54.08 M |
| Equity | 64.72 M | 128.81 M | 216.74 M | 321.33 M |
| Current Assets | 204.34 M | 299.85 M | 422.79 M | 311.71 M |
| Current Liabilities | 48.55 M | 57.53 M | 62.79 M | 29.83 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -19.27 M | -78.76 M | -103.15 M | -84.78 M |
| Investing CF | 40.35 M | 58.23 M | -53.58 M | 54.9 M |
| Financing CF | -26.62 M | -27.63 M | 198.13 M | 20.03 M |
| Free CF | -32.17 M | -96.71 M | -112.21 M | -86.91 M |
| Capex | -12.9 M | -17.95 M | -9.06 M | -2.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -14.61% | -8.07% | — | — |
| Earnings Growth % | 13.28% | -9.91% | — | — |
| Profit Margin % | -171.58% | -168.95% | -141.31% | — |
| Operating Margin % | -179.92% | -173.23% | -143.74% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -154.52% | -155.9% | -138.36% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.